Dendritic cells and tumor immunity

Seminars in Immunology

Volumn 13, Issue 5, 2001, Pages 291-302

  Gunzer, Matthias ^a   Jänich, Sabine ^a   Varga, Georg ^a   Grabbe, Stephan ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Clinical studies; Dendritic cell; Dendritic cell tumor; Immunotherapy of cancer; Tumor

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; HUMAN; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

EID: 0034891346     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.2001.0325     Document Type: Article

References (136)

1. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
2. Immune surveillance against a solid tumor fails because of immunological ignorance
3. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
4. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
5. Tumor immunology
6. Detection of minimal residual disease in patients with cancer: A review of techniques, clinical implications, and emerging therapeutic consequences
7. CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease
8. Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma
9. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
10. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
11. Dendritic cells and the control of immunity
12. Immunobiology of dendritic cells
13. Dendritic cells: Unique leukocyte populations which control the primary immune response
14. The concept of immunological surveillance
15. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells
16. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T
17. The central role of CD4(+) T cells in the antitumor immune response
18. CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes
19. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
20. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis
21. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
22. Tolerance, danger, and the extended family
23. The expanding 37 superfamily: Increasing complexity in costimulatory signals regulating T cell function
24. + T-helper and a T-killer cell
25. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
26. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
27. Human dendritic cells mediate cellular apoptosis via the tumor necrosis-factor-related apoptosis-inducing ligand (TRAIL)
28. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells
29. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells
30. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers
31. Langerhans' cells and lymphocytic infiltrate in AIDS-associated Kaposi's sarcoma. An immunohistochemical study
32. Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin
33. Langerhans cells in various benign and malignant pigment-cell lesions of the skin
34. Presentation of tumor antigens by Langerhans cells and other dendritic cells
35. Bioactive tumour necrosis factor alpha but not granulocyte-macrophage colony-stimulating factor correlates inversely with Langerhans's cell numbers in skin tumours
36. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration
37. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake
38. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade
39. Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: A prognostic study
40. Human renal-cell carcinoma tissue contains dendritic cells
41. Langerhans cell density in epithelial skin tumors correlates with epithelial differentiation but not with the peritumoral infiltrate
42. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer
43. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell costimulatory molecules and are impaired as antigen-presenting cells
44. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation
45. Dendritic cells in cancer immunotherapy
46. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells
47. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells
48. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells
49. Differential effects of corticosteroids during different stages of dendritic cell maturation
50. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10
51. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation
52. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review
53. Histiocytosis X histogenetic arguments for a Langerhans cell origin
54. Hodgkin's cells express CD83, a dendritic cell lineage associated antigen
55. Malignant lymphoma of plasmacytoid T-cells. Morphologic and immunologic studies characterizing a special type of T-cell
56. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?
57. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
58. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
59. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
60. Local therapy with biologic agents
61. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors
62. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
63. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo
64. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo
65. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but not CD11b-(low)CD11c(high) murine dendritic cells in vivo: A comparative analysis with Flt3 ligand
66. Dendritic cells require maturation via CD40 to generate protective antitumor immunity
67. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant
68. Dendritic cells as adjuvants for immune-mediated resistance to tumors
69. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
70. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours
71. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
72. Gene-modified tumor cells as cellular vaccine
73. Tumor immunotherapy: The tumor cell as an antigen-presenting cells
74. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
75. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
76. The role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
77. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
78. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
79. Cytokine-secreting tumor cell
80. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study
81. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells
82. The dendritic cell system and its role in immunogenicity
83. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
84. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
85. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
86. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
87. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
88. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
89. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: Implications for studies on antigen-presenting cell function and immunotherapy
90. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
91. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
92. Dendritic cell regulation of Th1-Th2 development
93. Reciprocal control of T helper cell and dendritic cell differentiation
94. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent Th1 polarization
95. Kinetics of dendritic cell activation: Impact on priming of Th1, Th2 and nonpolarized T cells
96. Dendritic cells: Multi-lineal and multi-functional
97. The makings of a tumor rejection antigen
98. Dendritic cells in cancer immunotherapy
99. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
100. Human tumor antigens recognized by T lymphocytes
101. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes
102. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
103. A new era for cancer immunotherapy based on the genes that encode cancer antigens
104. Serological analysis of human tumor antigens: Molecular definition and implications
105. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
106. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
107. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells
108. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendriti cells
109. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
110. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
111. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha
112. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer
113. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
114. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells
115. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells
116. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
117. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
118. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells
119. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
120. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells
121. The in-vitro generation of dendritic cells from blast cells in acute leukaemia
122. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells
123. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
124. Serological detection of cutaneous T-cell lymphoma-associated antigens
125. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia
126. Identification of cancer antigens in breast cancer by the SEREX expression cloning method
127. SEREX analysis of gastric cancer antigens
128. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer
129. Definition of tumor-associated antigens in hepatocellular carcinoma
130. Antigens recognized by autologous antibody in patients with renal-cell carcinoma
131. Characterization of human colon cancer antigens recognized by autologous antibodies
132. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo
133. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
134. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy